Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:23:56.776Z.
Calculation as of: 2026-10-06T16:23:56.776Z.
Quote observation: 2026-10-06T16:20:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869efbf6e11e98c8b36b953a9b631e7639c239a9e2012f11ad9cca4b0e6b7a7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$669.77M
EV/EBITDA Ratio
26.24x
TTM Avg
12.95x
3Y Avg
19.43x
5Y Avg
199.83x
Market Cap
$670.70M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $650.93M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.27M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $633.99M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $632.18M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | 26.24x | 12.95x | 19.43x | 199.83x |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $670.70M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $678.13M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $677.18M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $685.54M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $690.35M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
